Showcase Track S1 - January 25 9.30 A.M.-3.00 P.M.,Showcase Track S1 - January 26 10.00 A.M.-10.15 A.M.,Showcase Track S1 - January 27 11.45 A.M.-12.00 P.M.
The PMWC 2023 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
Confirmed Presenting Companies:
Speaker Profile
PHD, CEO/CSO, Phase Genomics, Inc.
Biography
Leads Phase Genomics in both executive and technical roles.
Talk
Genomic Profiling Showcase:
Phase Genomics, Inc.
Phase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture.
High-Resolution Cytogenomics Using Proximity Ligation Sequencing
Our new OncoTerra platform enables comprehensive detection of chromosomal aberrations in diverse samples, including FFPE.
Speaker Profile
Chief Operating Officer, PacBio
Biography
Mark joined PacBio as Chief Operating Officer where he manages our research, development, and manufacturing organizations and is responsible for driving our strategic planning and corporate development activities. Mark joined the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees. Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics. He earned as BS in Biochemistry from Western University and was a PhD candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.
Talk
Genomic Profiling Showcase:
PacBio
PacBio Systems are powered by Single Molecule, Real-Time Sequencing and provide comprehensive views of genomes, transcriptomes, and epigenomes. As the only sequencing technology to offer highly accurate long reads (HiFi reads), PacBio provides unparalleled access to the full spectrum of genetic variation in any organism
PacBio for the Future
PacBio for the Future
Speaker Profile
M.D., MPH, FACP, Sr. VP & Global Head of Enterprise Oncology, Labcorp
Biography
Dr. Reddy has played an integral role in advancing oncology efforts at Labcorp dedicated to advancing precision oncology to improve patient outcomes. Since joining Labcorp, he oversaw the acquisitions of OmniSeq and PGDx expanding Labcorp’s leading oncology portfolio of NGS-based genomic profiling capabilities. He previously served as VP of Medical Affairs at Foundation Medicine. He is triple board-certified in internal medicine, medical oncology, and hematology. Dr. Reddy earned his medical degree from the University of Kansas Medical Center, where he completed his internal medicine residency and clinical hematology/oncology fellowship. He obtained a master’s degree in public health (MPH) through a NIH Clinical Research Curriculum Award (K30) program and is an alumnus of Harvard Business School. Additionally, he is a fellow of the American College of Physicians. Dr. Reddy is a Lt. Col. in the U.S. Air Force Reserve, with over 17 years of service.
Talk
Genomic Profiling Showcase:
Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and lives.
Personalized Clinical Decision Support Leveraging Data Driven Insights
Harnessing technologies, increasing therapeutics access, and extracting data insights to improve outcomes and reduce healthcare costs.
Speaker Profile
PharmD, Ph.D., Associate Professor Department of Clinical Pharmacy, UCSF
Biography
Dr. Tamraz primary interest is identification of genetic determinants of drug response through modern methods aimed at addressing pharmacogenomics research and translating that information into new diagnostics and treatment strategies at pointofcare.
Genomic Profiling Showcase:
UCSF
Speaker Profile
M.D., Executive Vice President and Chief Medical Officer, Caris Life Sciences
Biography
George W. Sledge, Jr., M.D. oversees Caris Life Sciences’ medical affairs, research, and medical education, including oversight and leadership for the Caris Precision Oncology Alliance™ and Caris’ global team of Medical Science Liaisons. Prior to joining Caris, Dr. Sledge was Professor of Medicine at the Stanford University School of Medicine where he served as a member of the Division of Oncology. He was most recently co-director of the Stanford Cancer Institute’s Cancer Therapeutics Program and served from 2013-2020 as Chief of the Division of Oncology. Trained in Internal Medicine and Medical Oncology, Dr. Sledge has devoted his professional career to understanding the biology and improving the treatment of breast cancer. He is active as both a laboratory and clinical researcher, with more than 390 scientific publications.
Talk
Genomic Profiling Showcase:
Caris Life Sciences
Caris Life Sciences®, the leading molecular science and technology company developing and delivering innovative solutions to revolutionize healthcare, has a suite of market-leading molecular profiling offerings that assess DNA, RNA and proteins, revealing a molecular blueprint helping physicians better detect, diagnose and treat patients.
The Benefits of Comprehensive Molecular Profiling
How Whole Exome and Whole Transcriptome Sequencing can lead to better patient outcomes.
Speaker Profile
Ph.D., Sr. Director, Research & Development, Thermo Fisher
Biography
Currently, Robert Balog leads Thermo Fisher Scientific’s Microarray R&D team, responsible for developing next generation Microarray hardware, software, and assay workflows to support the clinical and research genomics markets. Prior to his current role he led the clinical system engineering team responsible for Thermo Fisher’s Amplitude High Throughput SARS-CoV-2 testing platform. Robert has over 15 years of experience in product development from basic biomarker discovery to on market support of diagnostic testing systems in both genomics and proteomics. Prior to Thermo Fisher, he spent 3 years as CEO and cofounder of BioCeryx developing automated microfluidic devices for noninvasive prenatal testing and 14 years as a Program Manager at SRI International developing host response IVDs for radiation exposure and integrated nucleic acid analysis systems. Dr. Balog has a Ph.D. in Biomedical Engineering from the University of Texas, Southwestern Medical Center at Dallas and a BE in Molecular Biology and Biomedical Engineering from Vanderbilt University.
Talk
Genomic Profiling Showcase:
Thermo Fisher
Thermo Fisher Scientific is the world leader in serving science. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.
Advancing tools to drive Precision Medicine to Predictive Medicine
Learn how Thermo Fisher Scientific's Axiom technology is driving advances in precision medicine programs
